A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

NCT05851924 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: NALIRIFOX
COMBINATION_PRODUCT: AD-XRT and Capecitabine

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]